

# Cancer Screening Program (CaSP) General Information Sheet

CaSP is the screening program associated with Omico's landmark initiative, PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials)



Cancer  
meets its match



Cancer is a disease that arises from gene changes in normal cells. Knowing which gene changes cause a particular cancer has allowed us to develop treatments that target those changes. Unlike traditional treatments, 'targeted' therapies have led to significant improvements in stopping cancers from growing, or even in some instances stopping them completely.

## What is CaSP?

Cancer Screening Program (CaSP) is the screening program associated with ProSPeCT, which brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products. There are three interrelated components of CaSP:

- CaSP enables access to Comprehensive Genomic Profiling (CGP) for 23,000 patients in Australia with incurable or advanced cancer, at no cost to the patient. The results are then reviewed by Omico's Molecular Oncology Board (MOB), which provides a report to the referring clinician, including potential clinical trials for patients.
- Observational cohort study of people enrolled in CaSP
- Research Registry and Biobank to facilitate ongoing research into cancer and its treatment.

## How can a patient participate in CaSP?


Participation in CaSP requires referral from a patient's treating oncologist. Referrals are completed online, using the [Referral Form LINK](#).

## What tumour tissue is required for CGP with CaSP?

Biospecimen that has been taken from previous procedures such as tissue resections, diagnostic biopsies, core needle biopsies or fine needle aspirations (guided by CT, EBUS or EUS). For details on optimal surface area, volume and tumour cellularity, please contact a member of the CaSP study team.

## How long does CGP take?

Once a patient has provided written consent to participate in CaSP, it typically takes 8-10 weeks for the referring clinician to receive the MOB report. Patients indicated as urgent by the referring clinician will be fast-tracked, with MOB reports returned in 5-6 weeks.



### To participate in CaSP, patients must:

- Be 16 years and older, and
- Have pathologically confirmed, incurable, advanced or metastatic cancer.

Patients must meet all the inclusion criteria and none of the exclusion criteria to be eligible for inclusion in the CaSP.

## Inclusion Criteria

Patients must fulfil all of the following criteria to be eligible for this study.

- I. Male or female patients, aged 16 years and older, with pathologically confirmed incurable, advanced and/or metastatic tumour of any histologic type or an earlier diagnosis of a poor prognosis tumour;
- II. Life expectancy of equal to or greater than 3 months;
- III. Sufficient and accessible tissue for molecular screening;
- IV. ECOG performance status 0, 1 or 2;
- V. Willingness to comply with all protocol requirements, including long-term follow-up, and instructions from study staff;
- VI. Patients with primary central nervous system (CNS) tumours, with stable neurological function, on stable doses of steroids/anti-epileptics over at least a 4-week period are eligible; and
- VII. Provide written informed consent

## Exclusion Criteria

Patients with any one of the following characteristics will not be eligible for this study.

- I. Co-morbidities or conditions that may compromise assessment of key outcomes or in the opinion of the clinician, limit the ability of the patient to comply with the protocol;
- II. For non-central nervous system (CNS) cancers, patients with symptomatic CNS involvement of his/her cancer are excluded.
- III. History of another malignancy within 2 years prior to consent are excluded unless adequately treated and determined free of progressive and metastatic disease for at least 6 months.

For more information please email us at: [casp@omico.org.au](mailto:casp@omico.org.au) or call 1800 954 350